Fulgent Genetics Inc. – Material Contracts Watch

from 8-K 11 pages Fulgent Genetics, Inc. Stock Option Grant Notice Stock Option Grant Under the Company’s 2026 Equity Incentive Plan

from 8-K 7 pages Fulgent Genetics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant Under the Company’s 2026 Equity Incentive Plan

from 8-K 15 pages Fulgent Genetics, Inc. 2026 Equity Incentive Plan 1. Definitions. Unless Otherwise Specified or Unless the Context Otherwise Requires, the Following Terms, as Used in This Fulgent Genetics, Inc. 2026 Equity Incentive Plan, Have the Following Meanings: “Administrator” Means the Board of Directors, Unless It Has Delegated Power to Act on Its Behalf to the Committee, in Which Case the Term “Administrator” Means the Committee. “Affiliate” Means a Corporation or Other Entity, Which, for Purposes of Section 424 of the Code, Is a Parent or Subsidiary of the Company, Direct or Indirect. “Agreement” Means a Written or Electronic Document Setting Forth the Terms of a Stock Right Delivered Pursuant to the Plan, in Such Form as the Administrator Shall Approve. “Board of Directors” Means the Board of Directors of the Company

from 10-Q 5 pages Assignment and Assumption of Lease

from 10-Q 22 pages Commercial Lease Agreement

from 8-K 87 pages Asset Purchase Agreement by and Among Bako Pathology LP, Bako Pathology Holdings Corp., Bpa Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., Gbrl Consulting, LLC, Fulgent Therapeutics, LLC, and Inform Diagnostics, Inc. Dated as of December 20, 2025

from 8-K 92 pages Purchase and Sale Agreement by and Among Bako Pathology LP, as Parent, Bako Pathology Holdings Corp., as Holdings, Bpa Holding Corp., as Seller, Dermatopathology Experts, LLC, as the Company, Fulgent Therapeutics, LLC, as Buyer Parent (Solely for Purposes of ‎section 11.16 (And ‎article XI as It Relates to ‎section 11.16)), and Inform Diagnostics, Inc., as Buyer Dated as of December 20, 2025

from 10-Q 3 pages Fulgent Genetics, Inc. Amended and Restated Director Compensation Program

from 10-K 5 pages Rule 10b5-1 Issuer Repurchase Plan

from 10-Q 6 pages Fulgent Genetics, Inc. Amended and Restated Executive Officer Incentive Plan Effective October 30, 2023

from 10-Q 6 pages Fulgent Genetics, Inc. Amended and Restated Incentive Compensation Recoupment Policy

from 8-K 13 pages Fulgent Genetics, Inc. Amended and Restated 2016 Omnibus Incentive Plan

from 10-Q 5 pages Fulgent Genetics, Inc. Executive Officer Incentive Plan Effective January 1, 2023

from 10-Q 3 pages Fulgent Genetics, Inc. Amended and Restated Director Compensation Program

from 10-K 13 pages Fulgent Pharma Holdings, Inc. 2022 Omnibus Incentive Plan

from 10-K 45 pages Lease of Premises at 15-19 Crawford Street Needham, Massachusetts From Crawford Street De, LLC to Miraca Life Sciences, Inc

from 10-K 4 pages Second Amendment to Lease

from 10-K 11 pages First Amendment and Partial Restatement of Lease

from 10-K 12 pages Background: 1. Incorporation. the Above Background Is Incorporated Herein by Reference

from 10-K 5 pages Rule 10b5-1 Issuer Repurchase Plan